Get started
Author

Dorothée Sémiond

Observed names: D Sémiond, D. Semiond, D. Sémiond, Dorothee Semiond, Dorothée Semiond, Dorothée R. Sémiond, Dorothée Semiond
Observed institutions: Cliniques Universitaires Saint-Luc, American Association For Cancer Research, Institut Jules Bordet, Erasmus MC, Sanofi (France), Sanofi (United States), National Cancer Institute, Erasmus MC Cancer Institute, Daniel den Hoed Kliniek
OpenAlex ID: A5087080285
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
2009 · Alain C. Mita, Louis J. Denis, et al. · Clinical Cancer Research · 333
Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors
2013 · Patricia Vrignaud, Dorothée Sémiond, et al. · Clinical Cancer Research · 230
Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and rats
2003 · Salvatore Cisternino, Fanchon Bourasset, et al. · British Journal of Pharmacology · 111
PDF
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
2019 · Joseph Mikhael, Paul Richardson, et al. · Blood · 90
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
2021 · Joseph Mikhael, Karim Belhadj-Merzoug, et al. · Blood Cancer Journal · 88
PDF
Preclinical profile of cabazitaxel
2014 · Patricia Vrignaud, Veronique Benning, et al. · Drug Design Development and Therapy · 88
PDF
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer
2005 · D.W. Rea, J.W.R. Nortier, et al. · Annals of Oncology · 80
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
2020 · Meletios A. Dimopoulos, Xavier Leleu, et al. · Leukemia · 73
PDF
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study
2011 · C. Villanueva, A. Awada, et al. · European Journal of Cancer · 65
Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study
2012 · V. Diéras, A. Lortholary, et al. · European Journal of Cancer · 63
PDF
Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein
2018 · George E. Duran, Volker Derdau, et al. · Cancer Chemotherapy and Pharmacology · 50
Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors
2013 · Géraldine M. Ferron, Yang Dai, et al. · Cancer Chemotherapy and Pharmacology · 44
PDF
Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors
2002 · C. Sessa, C. Cuvier, et al. · Annals of Oncology · 44
PDF
Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant
2023 · Flavio Vincenti, Oriol Bestard, et al. · Journal of the American Society of Nephrology · 42
Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel
2013 · D. Sémiond, S. S. Sidhu, et al. · Cancer Chemotherapy and Pharmacology · 36
Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844)
2016 · Antonio Ugolini, Mireille Kenigsberg, et al. · Journal of Medicinal Chemistry · 32
Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients
2020 · Jean‐Baptiste Fau, Raouf El‐Cheikh, et al. · CPT Pharmacometrics & Systems Pharmacology · 30
PDF
Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors
2005 · Otto Soepenberg, Herlinde Dumez, et al. · Journal of Clinical Oncology · 28
Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours
2013 · Pierre Fumoleau, Jose Manuel Trigo, et al. · BMC Cancer · 24
PDF
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
2025 · Sikander Ailawadhi, Ivan Špička, et al. · Journal of Clinical Oncology · 22
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma
2021 · Kimiko Koiwai, Raouf El‐Cheikh, et al. · CPT Pharmacometrics & Systems Pharmacology · 21
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours
2006 · H. Dumez, A. Awada, et al. · Annals of Oncology · 20
A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors
2014 · Laurence Ridoux, Dorothée R. Sémiond, et al. · Anti-Cancer Drugs · 17
Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone
2021 · Hoai‐Thu Thai, Nadia Gaudel, et al. · British Journal of Clinical Pharmacology · 14
PDF
Novel Taxanes: Cabazitaxel Case Study
2012 · Hervé Bouchard, Dorothée Semiond, et al. · 14
Works count: 80
Citation count: 1,757
H-index: 21
I10-index: 27
Year
Topic
Type